BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (January 2014)

22 slides from BioSpecifics Technologies's investor presentation, Jan 13, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Pa . i } ae >. sae " Innovators in the development & commercialization of “ “INJECTABLE _£ COLLAGENASE B oSpec fics January 2014 TECHNOLOGIES CORP

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Company Overview

    Company Overview BioSpecifics is a profitable, commercial-stage biopharma company developing injectable collagenase marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the US and XIAPEX® (the EU tradename for CCH) XIAFLEX Now Marketed for Two Indications in US New FDA-Approved Indi

  4. Slide 4: Vast Therapeutic Potential

    Vast Therapeutic Potential CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications in the clinic: Dupuytren’s contracture

  5. Slide 5: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand that causes one or more fingers to Definition & contract toward the palm, limiting range of motion of the fingers Key Complications Often results in physical disability, significantly affecting quality of life and daily act

  6. Slide 6: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture sBLA for Label Expansion Filed in 4Q13 * Positive top-line data reported from Phase 3b MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren’s) study Evaluated XIAFLEX for the concurrent treatment of adult Dupuytren’s co

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Data from Multiple Studies Presented at ASSH Collagenase Optimal Reduction croupuyeren sc tonetern CORDLESS is a five-year observational study designed to assess the rates of . recurrence following treatment with XIAFLEX, as well as long-term safety and Evaluation

  8. Slide 8: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity, which can result in pain with erection, penile shortening, indentations, erectile Definition & ldyefanction and /ondifficilty witli eexucl intercourse =Incevere cases penis Key Complications can bend at 9

  9. Slide 9: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Approval Based on Positive Results from IMPRESS Trials IMPRESS" | and II clinical trial design ~ Two randomized (2:1 of 0.58 mg CCH or placebo) double-blind Phase 3 trials in over 800 patients at 64 sites in US and Australia, with 52-week follow up Men received up to 8

  10. Slide 10: Deep Clinical Pipeline

    Deep Clinical Pipeline Dupuytren’s FDA to review sBLA filed for multi-cord label expansi Contracture jek aoa . Sobi to file MAA for approval in EU Disease FREER Gopehne data expected fron phase beech Shoulder pening Chien-804 I study tin 1Q14 Lipoma ien-804 final study report in * CAEN Initiate plac

  11. Slide 11: CCH for Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition & the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans. Can be a serious health problem in dogs

  12. Slide 12: CCH for Canine Lipomas

    CCH for Canine Lipomas Chien-804 Placebo-Controlled Phase 2 Trial BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in dogs with benign subcutaneous lipomas 37 dogs randomized, single injection 1:1 CCH to placebo Primary efficacy endpoint: Relative change in lipoma

  13. Slide 13: CCH for Human Lipomas

    CCH for Human Lipomas Dose Escalation Phase 2 Clinical Trial BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas 14 patients received single injections of one of four ascending dosage groups ranging from 0.058 mg to 0.44 mg CCH — Prim

  14. Slide 14: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Preclinical Studies Ongoing Definition & Key Complications Potential to be Nonsurgical Therapy Option US Market Opportunity Ongoing ork AD, Banks NK Henne MB. Sea Benign tumors with significant co- morbidities, which can include pain, decreased fertility, increased rate of m

  15. Slide 15: Frozen Shoulder — Statistically Significant

    Frozen Shoulder — Statistically Significant CCH Dose Response in Phase 2a Study 60. / \ Both the 0.58 mg(1mL) and 0.58 mg(2mL) babe "Forward Flexion cohort demonstrated statistically significant co Reber + Shoulder Abduction improvement over baseline scores vs. the [ 1 Extemal Rotation exercise-only

  16. Slide 16: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Phase 2b Trial Initiated in 4Q13 Inflammation and thickening of shoulder Definition & capsule due to collagen accumulation, Key Complications Condition often limits the range of motion of the shoulder No FDA-approved pharmaceutical Potential to be Only therapies avai

  17. Slide 17: CCH for Cellulite

    CCH for Cellulite Top-line Data from Phase 2a Study Expected in 1Q15 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Data from Phase 2a Study Expected in 1Q15 Phase 2a Study Based on Phase 1b Trial Source of data: Auxilium Pharmaceuticals, Ine. Skin dimpling as a resu

  18. Slide 18: Auxilium Partnership

    Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of CCH >$36M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Potential Royalties from Second Indication Auxilium Opt-In Rights Ex-US Strategic Partnerships Over $36M total

  19. Slide 19: Corporate Highlights

    Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: * Dupuytren’s contracture: XIAFLEX has Orphan Drug protection in US until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s disease: Auxil

  20. Slide 20: Consistently Profitable Annually

    Consistently Profitable Annually 3Q13 Financial Highlights For the quarter For the year ended ended 09/30/13 12/31/12 (unaudited) (unaudited) Cash and equivalents, short term investments S$ 11,333,942 $ 8,503,737 Income Statement Revenues § 3,145,123 $ 11,145,078 Other income 7,134 34,634 Costs and

  21. Slide 21: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Q Initiate placebo-controlled trial in 1H14 Lipomas Q Complete enrollment in placebo-controlled trial in 4Q14 *Canine Q Chien-804 final study report in 1Q14 Lipomas Q 120 day opt-in period

  22. Slide 22: Pa . i }

    Pa . i } ae >. sae " Innovators in the development & commercialization of “ “INJECTABLE _£ COLLAGENASE B oSpec fics January 2014 TECHNOLOGIES CORP

BioSpecifics Technologies — Investor Presentation (January 2014) on 6ix